REBECCA YANG, PHARMD
Pharmacy at Sunset Blvd, Los Angeles, CA
License number
California 55160
Category
Pharmacy
Type
Pharmacist
Address
Address
1625 W Sunset Blvd, Los Angeles, CA 90026
Phone
(213) 482-9286
Personal information
See more information about REBECCA YANG at radaris.comName
Address
Phone
3149 Alexis Dr, Palo Alto, CA 94304
7168 Rainbow Dr, San Jose, CA 95129
550 Los Arbolitos Blvd APT 85, Oceanside, CA 92058
4535 Chateau Dr, San Diego, CA 92117
104 Summerset Ct, San Ramon, CA 94583
Professional information
Occupational Therapist R/L At Center For Developing Kids
Position:
Occupational Therapist R/L at Center for Developing Kids, Occupational Therapy Student at University of Southern California
Location:
Los Angeles, California
Industry:
Health, Wellness and Fitness
Work:
Center for Developing Kids
since Dec 2012
-
Occupational Therapist R/L
University of Southern California
- University of Southern California since May 2010
-
Occupational Therapy Student
Holding Hands Pediatric Therapy
- Burbank 2011 - 2012
-
Floortime Therapist
Education:
UCLA
Bachelor of Science (BS), Psychobiology USC
Master of Arts (M.A.), OT
Bachelor of Science (BS), Psychobiology USC
Master of Arts (M.A.), OT
Languages:
Mandarin
Senior Assistant To Chairman At Allis Communications Co., Ltd
Position:
senior assistant to chairman at allis communications co., ltd
Location:
Greater Los Angeles Area
Industry:
Telecommunications
Work:
allis communications co., ltd
-
senior assistant to chairman
Induction Of Antigen Specific Immunnologic Tolerance
US Patent:
7883707, Feb 8, 2011
Filed:
Mar 27, 2009
Appl. No.:
12/412986
Inventors:
Emil D. Kakkis - Novato CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US
International Classification:
A61K 39/385
US Classification:
4241931, 4241981
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
Induction Of Antigen Specific Immunologic Tolerance
US Patent:
7485314, Feb 3, 2009
Filed:
May 6, 2002
Appl. No.:
10/141668
Inventors:
Emil D. Kakkis - Novato CA, US
Merry Passage - Torrance CA, US
Thomas Lester - Harbor City CA, US
Rebecca Yang - Los Angeles CA, US
Christopher Tanaka - Gardena CA, US
Merry Passage - Torrance CA, US
Thomas Lester - Harbor City CA, US
Rebecca Yang - Los Angeles CA, US
Christopher Tanaka - Gardena CA, US
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA
International Classification:
A61K 45/00
US Classification:
4242781, 424 941
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
Induction Of Antigen Specific Immunologic Tolerance
US Patent:
2004000, Jan 15, 2004
Filed:
May 5, 2003
Appl. No.:
10/429314
Inventors:
Emil Kakkis - Novato CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US
International Classification:
A61K038/13, A61K039/00
US Classification:
514/011000, 424/185100
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
Induction Of Antigen Specific Immunologic Tolerance
US Patent:
2005019, Sep 1, 2005
Filed:
Nov 3, 2004
Appl. No.:
10/980648
Inventors:
Emil Kakkis - Novato CA, US
Thomas Lester - Cardiff CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US
Thomas Lester - Cardiff CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US
International Classification:
A61K039/00, A61K038/13, A61K031/7024, A61K031/522
US Classification:
424184100, 514011000, 514263310, 514023000
Abstract:
Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.